Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Manhattan Scientifics's Total Liabilities for the quarter that ended in Jun. 2024 was $3.47 Mil. Manhattan Scientifics's Total Assets for the quarter that ended in Jun. 2024 was $0.07 Mil.
Therefore, Manhattan Scientifics's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2024 was 46.95.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Manhattan Scientifics Liabilities-to-Assets Related Terms
Manhattan Scientifics Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Manhattan Scientifics's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MHTX vs TBIO, CUTRQ, EMED: Liabilities-to-Assets Comparison
For the Medical Devices subindustry, Manhattan Scientifics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Manhattan Scientifics Liabilities-to-Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Manhattan Scientifics's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Manhattan Scientifics's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Manhattan Scientifics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Manhattan Scientifics (MHTX) has a Liabilities-to-Assets of 46.95 as of Jun. 2024. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Manhattan Scientifics and its competitors.
Is Manhattan Scientifics' Liabilities-to-Assets too high?
Manhattan Scientifics' current Liabilities-to-Assets is 46.95.
How does Manhattan Scientifics' Liabilities-to-Assets compare to TBIO and CUTRQ?
Manhattan Scientifics' Liabilities-to-Assets of 46.95 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Medical Devices & Instruments company?
A good Liabilities-to-Assets depends on the Medical Devices & Instruments industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Manhattan Scientifics and its competitors. Manhattan Scientifics's current Liabilities-to-Assets is 46.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Manhattan Scientifics stock overvalued right now?
Manhattan Scientifics (MHTX) has a current Liabilities-to-Assets of 46.95. The current Liabilities-to-Assets is 46.95. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Manhattan Scientifics (MHTX), the current Liabilities-to-Assets is 46.95 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Manhattan Scientifics Inc is a company operating as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in the areas of nano-technologies and nano-medicines. The company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, and scientists and leaders in industry and government. Its current focus is on the development of nanomaterials through the acquisition of Metallicum.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MHTX has been successfully added to your 
